H. Lee Moffitt Cancer Center and Research Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).

502 total trials 82 currently recruiting 280 completed early-phase tilt top decile by trial count

H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.

H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.

Top-decile sponsor footprint

H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

502 total, page 8 of 11

COMPLETED Phase 1

Phase I Trial of Combination of FOLFIRI and SOM 230

NCT01434069
COMPLETED Phase 1

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

NCT01446952
COMPLETED NA

Pilot Study on Focal Prostate Radio-Frequency Ablation

NCT01423006
COMPLETED Phase 1

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

NCT01324180
COMPLETED NA

Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy

NCT01422993
COMPLETED Phase 1

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

NCT01256268
COMPLETED Phase 1

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

NCT01385956
COMPLETED Phase 1

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

NCT01376453
TERMINATED Phase 1

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

NCT01286038
COMPLETED NA

Colorectal Cancer Awareness, Research, Education and Screening (CARES)

NCT01804179
COMPLETED Phase 2

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

NCT01253161
COMPLETED NA

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

NCT01253148
COMPLETED Phase 2

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

NCT01347034
TERMINATED Phase 2

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
COMPLETED NA

Evaluating Biobanking Educational Tools

NCT01672944
TERMINATED

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

NCT01455311
COMPLETED Phase 1

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
COMPLETED Phase 1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

NCT01176461
COMPLETED NA

Promoting a Healthier Lifestyle Among Breast Cancer Survivors

NCT01419613
COMPLETED Phase 1

Gem-TABS in Unresectable Pancreatic Carcinoma

NCT01198821
TERMINATED NA

Bicarbonate for Tumor Related Pain

NCT01350583
COMPLETED Phase 2

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

NCT01133275
COMPLETED Phase 1

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526
TERMINATED Phase 2

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

NCT01090973
COMPLETED Phase 2

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

NCT01054144
COMPLETED NA

Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer

NCT01419210
TERMINATED Phase 2

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

NCT01048723
COMPLETED Phase 1

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

NCT01042535
COMPLETED Phase 2

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

NCT01036321
COMPLETED NA

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
COMPLETED Phase 1

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
COMPLETED Phase 1

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

NCT00985777
COMPLETED Phase 2

Erlotinib Study for Myelodysplastic Syndrome (MDS)

NCT00977548
COMPLETED Phase 2

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT00955916
TERMINATED NA

Depocyt® With Sorafenib in Neoplastic Meningitis

NCT00964743
COMPLETED NA

Facts and Attitudes About Clinical Trials

NCT01269645
COMPLETED Phase 1

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

NCT00831766
COMPLETED Phase 2

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

NCT00948922
TERMINATED Phase 1

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

NCT00879073
TERMINATED Phase 2

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

NCT00858403
TERMINATED Phase 2

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

NCT00833859
COMPLETED Phase 1

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

NCT00840931
COMPLETED NA

Extended Self-Help for Smoking Cessation

NCT01352195
COMPLETED NA

Liposuction for Arm Lymphedema Following Breast Cancer Surgery

NCT00816985
COMPLETED NA

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551
COMPLETED NA

Relapse-Prevention Booklets as an Adjunct to a Tobacco Telephone Helpline("Quitline")

NCT01352000
COMPLETED NA

Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery

NCT01416168
COMPLETED Phase 1

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

NCT00798629
COMPLETED Phase 1

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

NCT00738751
COMPLETED NA

Managing Medication-induced Constipation in Cancer: A Clinical Trial

NCT01416909
← Previous Page 8 of 11 Next →

Phase Distribution

PhaseTrial count
Phase 1 167
Phase 2 168
Phase 3 3
Phase 4 2

Therapeutic Areas

Prostate Cancer 12
Pancreatic Cancer 11
Non-Small Cell Lung Cancer 11
Breast Cancer 10
HER2-positive Breast Cancer 7
Smoking Cessation 7
Lung Cancer 7
Leukemia 6
Acute Myeloid Leukemia 6
Triple Negative Breast Cancer 6

What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline

82 recruiting of 502 indexed (16% open); 280 completed (56%).

Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide

Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20% Total trials Recruiting share H. Lee Moffitt Cancer Center and Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)Gilead SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Boehringer IngelheimCase Western Reserve UniversityDrexel UniversityAtlantic Health SystemBioMarin Pharmaceutical
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 502 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this H. Lee Moffitt Cancer Center and Research Institute page

502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.

  • 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.